Two hundred and two patients with bone pain from metastatic cancer were treated with 40 , Ci/kg ofSr.89. Patients were followed with pain diaries, records ofmedication taken, sleep patterns, serial bone scans and a Karnofsky Index. One hundred and thirty-seven patients with adequate followup survived at least 3 months, including 100 with prostate and 28 with breast carcinoma. Eighty of the 100 patIents with prostate cancer responded, and 25 ofthe 28 breast cancer patients Improved. Ten patients wIth prostate cancer and five with breast cancer became pain free. Little hematologlc depression was noted. Sr89 kinetic studies showed that strontium taken up in osteoblastic areas remained for 100 days. The tumor#{149}to.marrow absorbed dose ratio was 10:1.

exclusion criteria. Seventh TNM edition was used. Totally 168 patients' demographic data, surgery types, clinical and pathological stage, pre-operative SUVmax and C/T ratio was recorded. Differences between patients with recurrence after surgery and without recurrence was demonstrated. Survival rates were analysed by divided into 3 groups according to C/T ratio (0.25-0.5, 0.5-0.75, 0.75-1.0) and cutoff value 50% of C/T ratio. Result: Two groups (C/T<0.5 and C/ T¼0.5-1) did not differ according to comparable factors like visceral pleural invasion, subtype of adenocarcinoma, median SUVmax. Median follow up time was 35 months. 54 patients were died of whom 8 (68%) patients were in C/T ratio<0.5 and 46 patients (67.8%) were in C/T¼0.5-1 group. OS was 44.9±5.07 and PFS was 50.8±5.42 in C/ T<0.5 group. OS was 69.7±3.34 and PFS was 77.2±3.23 in C/T¼0.5-1 group (p>0.05). Three-year survival rate was 50% for C/T <0.5 and 72% for C/T¼0.5-1 group (p>0.05).

No abstract

No abstract

Chemotherapy now has an established role in the treatment of non-small cell lung cancer, with randomised evidence supporting a survival benefit in both advanced disease and the adjuvant setting. The availability of newer cytotoxic agents has not led to further improvement in outcome, and novel approaches are needed. Growth factor-mediated signalling pathways are frequently subverted in human cancers, so that physiological processes become abnormally regulated by oncogene products such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF). Drugs targeting EGFR and VEGF have already demonstrated improved survival compared with standard of care in lung cancer, and the evidence supporting the use of these and related agents is reviewed here. These newer agents are in general cytostatic rather than cytotoxic, so that clinical benefit can be associated with stable disease rather than with disease response alone, and the impact of this on imaging modalities used to assess response in trials and clinical practice is discussed.